Omada Health (NASDAQ:OMDA) CAO Sells $13,994.12 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CAO Craig Gracey sold 644 shares of Omada Health stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $21.73, for a total transaction of $13,994.12. Following the completion of the transaction, the chief accounting officer directly owned 14,412 shares in the company, valued at $313,172.76. This represents a 4.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Craig Gracey also recently made the following trade(s):

• On Monday, August 10th, Craig Gracey sold 1,042 shares of Omada Health stock. The stock was sold at an average price of $25.00, for a total value of $26,050.00.
• On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The shares were sold at an average price of $23.00, for a total value of $14,651.00.
• On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The shares were sold at an average price of $22.00, for a total transaction of $8,910.00.
• On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $21.00, for a total transaction of $43,743.00.
• On Friday, June 26th, Craig Gracey sold 2,084 shares of Omada Health stock. The shares were sold at an average price of $20.00, for a total transaction of $41,680.00.
• On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $19.01, for a total transaction of $39,597.83.
• On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $18.00, for a total transaction of $37,494.00.

Omada Health Stock Performance

Omada Health stock opened at $19.66 on Monday. Omada Health, Inc. has a 52 week low of $10.28 and a 52 week high of $26.92. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of 393.20 and a beta of 1.86. The company has a 50 day moving average price of $22.63 and a 200 day moving average price of $17.97.

Omada Health (NASDAQ:OMDA) last released its earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. The company had revenue of $87.83 million during the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. Equities analysts forecast that Omada Health, Inc. will post 0.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omada Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in Omada Health in the second quarter worth approximately $32,000. Bellevue Group AG lifted its stake in shares of Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock valued at $5,567,000 after purchasing an additional 1,791 shares during the last quarter. Quarry LP bought a new stake in Omada Health in the fourth quarter worth $29,000. Barclays PLC boosted its holdings in Omada Health by 14.6% in the fourth quarter. Barclays PLC now owns 14,850 shares of the company’s stock worth $234,000 after purchasing an additional 1,888 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in Omada Health by 319.3% during the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock worth $66,000 after buying an additional 2,283 shares during the last quarter.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Analyst support remains strong: BTIG Research reaffirmed its “buy” rating and set a $35 price target, while Needham & Company also maintained a “buy” rating with a $28 target. These targets imply significant potential upside and reinforce confidence in Omada’s growth outlook.
• Positive Sentiment: Investor Day could provide new growth targets: Omada held its inaugural Investor Day and planned to present updated long-term financial targets. More ambitious revenue, profitability, or membership goals could improve investor confidence if management’s outlook exceeds current expectations. Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day
• Neutral Sentiment: Investor Day transcript available: The transcript may offer additional detail on Omada’s strategy and financial targets, but the supplied report does not identify specific changes that would immediately alter earnings expectations. Omada Health Analyst/Investor Day Transcript
• Negative Sentiment: Chief accounting officer sold shares: CAO Craig Gracey sold 644 shares for approximately $14,000, reducing his direct ownership by 4.28%. The relatively small transaction is not necessarily a sign of deteriorating fundamentals, but insider selling can create short-term negative sentiment. SEC Insider Transaction Filing

Analyst Ratings Changes

A number of brokerages have commented on OMDA. Citizens Jmp raised their price objective on Omada Health from $27.00 to $32.00 and gave the stock a “market outperform” rating in a research report on Friday, August 14th. Robert W. Baird upped their target price on Omada Health from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Weiss Ratings raised shares of Omada Health from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, August 11th. Barclays raised their price target on shares of Omada Health from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Omada Health from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Omada Health presently has a consensus rating of “Moderate Buy” and an average price target of $26.67.

Omada Health Company Profile

Omada Health, Inc is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines clinical care, health coaching, connected devices, digital tools and personalized support to help members improve health outcomes and manage conditions over time.

The company’s offerings address areas including diabetes, hypertension, weight health and musculoskeletal conditions. Omada’s programs are designed to support prevention and ongoing care through services such as remote monitoring, personalized health guidance, educational content and access to healthcare professionals.

Omada primarily serves members through employers, health plans and healthcare organizations in the United States.